Malignant Pleural Mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure, with a latency period of about 40 years before symptoms appear. Despite affecting a minority of exposed individuals, its risk escalates with prolonged exposure. Originating from mesothelial cells, [ Malignant Pleural Mesothelioma (MPM) ] affected 30,870 … [Read more...]
Predictive potential of MRI in differentiating the predominant component in biphasic pleural mesothelioma
Purpose: To assess the potential of apparent diffusion coefficient (ADC) values derived from diffusion weighted (DW) MRI preoperatively to predict the predominant histologic component among biphasic pleural mesothelioma (PM) tumors. Methods: ADC maps were generated from DW MRI scans. Histology and predominant component of [ biphasic pleural … [Read more...]
Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma
Asbestos exposure is known as the main elicitor of pleural mesothelioma (PM) development. The pathology’s rarity, wide range of growth patterns, and devastating prognosis have hindered a standardized treatment to date. This study intended to determine possible prognosticators contributing to adjusting the treatment allocation. This initiated the … [Read more...]
The U.S. banned asbestos, but its health impact will still be felt for decades
A new rule announced by the Environmental Protection Agency this week puts an end to the use of asbestos, a known carcinogen, in the United States. But researchers caution that we’ll likely still be dealing with the mineral’s public health harms for decades. The recently announced ban covers all forms of asbestos, including chrysotile asbestos, … [Read more...]
US Bans Sole Type of Asbestos, Parts Industries Still Import
The US will ban the only type of raw asbestos fiber known to be imported to the country [(chrysotile asbestos)] as part of a broader rule that also will ban all known uses of the cancer-causing mineral and imported equipment made with it, top EPA and White House officials announced on Monday. Many people are shocked to learn asbestos isn’t … [Read more...]
Impact of Surgery on Disease Progression and Survival of Patients with Pleural Mesothelioma
BACKGROUND: The effects of surgery on the survival of patients with pleural mesothelioma remain poorly understood. We compared the therapeutic outcomes of patients receiving neoadjuvant chemotherapy followed by surgery or refusing surgery for pleural mesothelioma. METHODS: This retrospective study included consecutive [ patients with pleural … [Read more...]
Pegargiminase Confers Survival Benefit in Nonepithelioid Pleural Mesothelioma
Adding pegargiminase to standard chemotherapy can improve outcomes in patients with chemotherapy-naïve, nonepithelioid pleural mesothelioma, according to research published in JAMA Oncology. [Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma. The ATOMIC-Meso … [Read more...]
FDA Fast Tracks UV1, Ipilimumab, and Nivolumab in Malignant Mesothelioma
The FDA has granted a fast track designation to the combination of UV1 with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma. This regulatory decision is supported by findings from the phase 2 NIPU trial which is evaluating UV1 in patients with unresectable malignant pleural mesothelioma. … [Read more...]
A Complete Response to Pembrolizumab in Malignant Peritoneal Mesothelioma: A Case Report
Abstract: Malignant peritoneal mesothelioma (MPeM) is a rare cancer of the peritoneum with a poor prognosis and nonspecific clinical course. We discuss a case of MPeM in a 59-year-old male who presented with abdominal pain and distension, without any known previous asbestos exposure. The diagnosis was made after a second biopsy finally confirmed … [Read more...]
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial
Introduction: Treatment of homologous recombination repair deficient (HRD)-tumours with PARP inhibitors has the potential to further increase tumour immunogenicity, suggesting a synergistic effect with immunotherapy. Here we present the preliminary results of [ combination of niraparib plus dostarlimab ] for pleural mesothelioma (PM) or non-small … [Read more...]